Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), LB Cluster Translational Oncology, 3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria.
Oncology. 2011;81(5-6):359-64. doi: 10.1159/000334919. Epub 2012 Jan 13.
Treatment of metastasized colorectal cancer (mCRC) patients with anti-epidermal growth factor receptor (EGFR)-directed monoclonal antibodies is driven by the results of the KRAS mutational status (wild type [WT]/mutated [MUT]). To find out as to what extent the treatment selection based on the KRAS status had impact on overall costs, a retrospective analysis was performed. Of 73 mCRC patients 31.5% were MUT carriers. Costs of EGFR inhibitor treatment for WT patients were significantly higher compared to those for patients with MUT (p = 0.005). Higher treatment costs in WT carriers reflect a significantly higher number of treatment cycles (p = 0.012) in this cohort of patients. Savings of drug costs minus the costs for the determination of KRAS status accounted for EUR 779.42 (SD ±336.28) per patient per cycle. The routine use of KRAS screening is a cost-effective strategy. Costs of unnecessary monoclonal EGFR inhibitor treatment can be saved in MUT patients.
转移性结直肠癌（mCRC）患者的表皮生长因子受体（EGFR）靶向单克隆抗体治疗受 KRAS 突变状态（野生型 [WT]/突变型 [MUT]）的结果驱动。为了了解基于 KRAS 状态的治疗选择对总费用的影响程度，进行了一项回顾性分析。在 73 名 mCRC 患者中，31.5%为 MUT 携带者。与 MUT 患者相比，WT 患者的 EGFR 抑制剂治疗费用明显更高（p = 0.005）。WT 携带者的治疗费用较高反映了该患者队列中治疗周期的数量明显更多（p = 0.012）。每个周期药物成本减去 KRAS 状态确定成本的节省为每位患者 779.42 欧元（SD ±336.28）。常规进行 KRAS 筛查是一种具有成本效益的策略。可以节省 MUT 患者中不必要的单克隆 EGFR 抑制剂治疗的费用。
